Advances in Management and Applied Economics

Standardization for innovation: The adoption of drug entity identification in the pharmaceutical industry for public health

• [ Download ]
• Times downloaded: 9195

• Abstract 

  Whether the pharmaceutical factory has already performed in-plant drug entity identification, whether the newly-developed drug product has implemented drug entity identification, the government aspect of company cooperation with the Department of Health to subsidize pharmaceutical factories to implement drug entity identification, the government aspect of the Department of Health arranging project grants to encourage the pharmaceutical factories to implement drug entity identification, the government aspect of the government’s need to mandate regulations for drug entity identification, the government aspect of the government’s need to continue to provide subsidies to pharmaceutical factories to implement drug entity identification, the implementation aspect of drugs should implement entity identification, the implementation aspect of company belief that the implementation of drug entity identification is most needed by the public, the implementation aspect of company belief that the implementation of drug entity identification is most needed by medical institutions, the benefit aspect of company belief that the implementation of drug entity identification is most beneficial to medical institutions, and  the cost aspect of company belief that the implementation of drug entity identification will increase the manufacturing costs of the pharmaceutical factories, have a significant impact on the willingness to cooperate. The site of the pharmaceutical factory had a significant impact on drug identification implementation, as shown by the Chi-square test. In addition, the proportion of domestic sales of pharmaceutical plants and the number of Western drug items had a significant impact on the ratio of drug entity identification, as found by the chi-square test.

  JEL classification numbers: C83, M15, O31
  Keywords: Standardization, Innovation, Drug Entity Identification, Public Health